Search Results - "OLENCKI, Thomas"

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma by Morris, John C, Tan, Antoinette R, Olencki, Thomas E, Shapiro, Geoffrey I, Dezube, Bruce J, Reiss, Michael, Hsu, Frank J, Berzofsky, Jay A, Lawrence, Donald P

“…In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human…”
Get full text

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial by Atkins, Michael B, Plimack, Elizabeth R, Puzanov, Igor, Fishman, Mayer N, McDermott, David F, Cho, Daniel C, Vaishampayan, Ulka, George, Saby, Olencki, Thomas E, Tarazi, Jamal C, Rosbrook, Brad, Fernandez, Kathrine C, Lechuga, Mariajose, Choueiri, Toni K

“…Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway have been characterised by excess toxicity,…”
Get full text

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update by Choueiri, Toni K., Hessel, Colin, Halabi, Susan, Sanford, Ben, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, George, Daniel, Morris, Michael J.

“…The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor…”
Get full text

Guidelines of care for the management of basal cell carcinoma by Bichakjian, Christopher, Armstrong, April, Baum, Christian, Bordeaux, Jeremy S., Brown, Marc, Busam, Klaus J., Eisen, Daniel B., Iyengar, Vivek, Lober, Clifford, Margolis, David J., Messina, Jane, Miller, Alexander, Miller, Stanley, Mostow, Eliot, Mowad, Christen, Nehal, Kishwer, Schmitt-Burr, Kristi, Sekulic, Aleksandar, Storrs, Paul, Teng, Joyce, Yu, Siegrid, Huang, Conway, Boyer, Kevin, Begolka, Wendy Smith, Alam, Murad, Kim, John Y.S., Kozlow, Jeffrey H., Mittal, Bharat, Moyer, Jeffrey, Olencki, Thomas, Rodgers, Phillip

“…Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early,…”
Get full text

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function by Stiff, Andrew, Trikha, Prashant, Mundy-Bosse, Bethany, McMichael, Elizabeth, Mace, Thomas A, Benner, Brooke, Kendra, Kari, Campbell, Amanda, Gautam, Shalini, Abood, David, Landi, Ian, Hsu, Vincent, Duggan, Megan, Wesolowski, Robert, Old, Matthew, Howard, John Harrison, Yu, Lianbo, Stasik, Nancy, Olencki, Thomas, Muthusamy, Natarajan, Tridandapani, Susheela, Byrd, John C, Caligiuri, Michael, Carson, William E

“…mAbs are used to treat solid and hematologic malignancies and work in part through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated…”
Get full text

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008) by Lacouture, Mario E., Morris, John C., Lawrence, Donald P., Tan, Antoinette R., Olencki, Thomas E., Shapiro, Geoffrey I., Dezube, Bruce J., Berzofsky, Jay A., Hsu, Frank J., Guitart, Joan

“…Fresolimumab is an antibody capable of neutralizing all human isoforms of transforming growth factor beta (TGFβ) and has demonstrated anticancer activity in…”
Get full text

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy by Khan, Shaheer, Lutzky, Jose, Shoushtari, Alexander N., Jeter, Joanne, Marr, Brian, Olencki, Thomas E., Cebulla, Colleen M., Abdel-Rahman, Mohamed, Harbour, J. William, Sender, Naomi, Nesson, Alexandra, Singh-Kandah, Shahnaz, Hernandez, Susana, King, Jeanelle, Katari, Manpreet S., Dimapanat, Lyssa, Izard, Stephanie, Ambrosini, Grazia, Surriga, Oliver, Rai, Alex J., Chiuzan, Codruta, Schwartz, Gary K., Carvajal, Richard D.

“…IntroductionApproximately 40% of patients with uveal melanoma (UM) will develop metastatic disease. Tumors measuring at least 12mm in basal diameter with a…”
Get full text

Surveillance strategies in the follow-up of melanoma patients: too much or not enough? by Kurtz, James, MD, Beasley, Georgia M., MD, Agnese, Doreen, MD, Kendra, Kari, MD, PhD, Olencki, Thomas E., DO, Terando, Alicia, MD, Howard, J. Harrison, MD

“…Abstract Background After appropriate initial therapy for patients with stage II-III melanoma, there is no consensus regarding surveillance. Thus, follow-up is…”
Get full text

Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab‐induced bullous pemphigoid by Ridpath, Alyson V., Rzepka, Polina V., Shearer, Sabrina M., Scrape, Scott R., Olencki, Thomas E., Kaffenberger, Benjamin H.

Get full text

The role of local therapy in the management of lung and liver oligometastases by Lo, Simon S, Moffatt-Bruce, Susan D, Dawson, Laura A, Schwarz, Roderich E, Teh, Bin S, Mayr, Nina A, Lu, Jiade J, Grecula, John C, Olencki, Thomas E, Timmerman, Robert D

“…The existence of a state of limited metastasis or oligometastasis observed in selected patients is associated with favorable outcomes. This Review discusses…”
Get full text

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma by Nghiem, Paul, Bhatia, Shailender, Lipson, Evan J, Sharfman, William H, Kudchadkar, Ragini R, Brohl, Andrew S, Friedlander, Philip A, Daud, Adil, Kluger, Harriet M, Reddy, Sunil A, Boulmay, Brian C, Riker, Adam, Burgess, Melissa A, Hanks, Brent A, Olencki, Thomas, Kendra, Kari, Church, Candice, Akaike, Tomoko, Ramchurren, Nirasha, Shinohara, Michi M, Salim, Bob, Taube, Janis M, Jensen, Erin, Kalabis, Mizuho, Fling, Steven P, Homet Moreno, Blanca, Sharon, Elad, Cheever, Martin A, Topalian, Suzanne L

“…BackgroundMerkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown…”
Get full text

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma by Suarez-Kelly, Lorena P., Levine, Kala M., Olencki, Thomas E., del Campo, Sara E. Martin, Streacker, Elizabeth A., Brooks, Taylor R., Karpa, Volodymyr I., Markowitz, Joseph, Bingman, Anissa K., Geyer, Susan M., Kendra, Kari L., Carson, William E.

Get full text

Case of sorafenib-induced thyroid storm by Haraldsdottir, Sigurdis, Li, Quan, Villalona-Calero, Miguel A, Olencki, Thomas E, Kendra, Kari, Ing, Steven W

Get full text

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma by Rini, Brian I., McDermott, David F., Hammers, Hans, Bro, William, Bukowski, Ronald M., Faba, Bernard, Faba, Jo, Figlin, Robert A., Hutson, Thomas, Jonasch, Eric, Joseph, Richard W., Leibovich, Bradley C., Olencki, Thomas, Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.

“…Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha…”
Get full text

F-18 Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Distant Metastases From Renal Cell Carcinoma by MAJHAIL, Navneet S, URBAIN, Jean-Luc, ALBANI, Justin M, KANVINDE, Mangesh H, RICE, Thomas W, NOVICK, Andrew C, MEKHAIL, Tarek M, OLENCKI, Thomas E, ELSON, Paul, BUKOWSKI, Ronald M

“…We conducted a study to evaluate the role of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) in the detection of distant metastases from renal…”
Get full text

A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma by GRIGNOL, Valerie P, OLENCKI, Thomas, CARSON, William E, RELEKAR, Kiran, TAYLOR, Cynthia, KIBLER, Amanda, KEFAUVER, Cheryl, LAI WEI, WALKER, Michael J, CHEN, Helen X, KENDRA, Kari

“…Bevacizumab is a humanized recombinant monoclonal antibody that neutralizes vascular endothelial growth factor, an agent with proangiogenic effects in…”
Get full text

Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis by Clarke, James W, Register, Steven, McGregor, John M, Grecula, John C, Mayr, Nina A, Wang, Jian Z, Li, Kaile, Gupta, Nilendu, Kendra, Kari L, Olencki, Thomas E, Cavaliere, Robert, Sarkar, Atom, Lo, Simon S

“…To examine the outcomes of patients with a single brain metastasis from radioresistant histologies (renal cell carcinoma and melanoma) treated with…”
Get full text

Transformation of facial basal cell carcinoma to squamous cell carcinoma following vismodegib by Silverman, Dustin A., Li, Michael M., Olencki, Thomas E., Seim, Nolan B., Teknos, Theodoros N., Kang, Stephen Y.

“…Vismodegib, a unique hedgehog pathway inhibitor, has been demonstrated to be effective in the treatment of non-operable and metastatic basal cell carcinoma…”
Get full text

Stereotactic radiosurgery alone for patients with 1–4 radioresistant brain metastases by Lo, Simon S., Clarke, James W., Grecula, John C., McGregor, John M., Mayr, Nina A., Cavaliere, Robert, Kendra, Kari L., Gupta, Nilendu, Wang, Jian Z., Sarkar, Atom, Olencki, Thomas E.

“…Brain metastases from radioresistant histologies are perceived to be less responsive to WBRT compared to other histologies, and stereotactic radiosurgery (SRS)…”
Get full text

Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics by Rossfeld, Kara, Hade, Erinn M, Gangi, Alexandra, Perez, Matthew, Kinsey, Emily N, Grabska, Joanna, Ederle, Ashley, Zager, Jonathan, Salama, April K, Olencki, Thomas E, Beasley, Georgia M

“…Immune checkpoint inhibitors have dramatically changed the prognosis for patients with metastatic melanoma. However, not all patients respond to therapy and…”
Get full text